Stock Analysis
- United States
- /
- Healthtech
- /
- NasdaqCM:ICAD
iCAD Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
iCAD (NASDAQ:ICAD) Full Year 2023 Results
Key Financial Results
- Revenue: US$17.3m (down 38% from FY 2022).
- Net loss: US$7.01m (loss narrowed by 49% from FY 2022).
- US$0.27 loss per share (improved from US$0.54 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
iCAD EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates by 39%.
Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.
Performance of the American Healthcare Services industry.
The company's shares are down 8.2% from a week ago.
Risk Analysis
Before you take the next step you should know about the 3 warning signs for iCAD that we have uncovered.
Valuation is complex, but we're helping make it simple.
Find out whether iCAD is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:ICAD
iCAD
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States.
Flawless balance sheet and slightly overvalued.